Latest Insider Transactions at Nektar Therapeutics (NKTR)
This section provides a real-time view of insider transactions for Nektar Therapeutics (NKTR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NEKTAR THERAPEUTICS to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NEKTAR THERAPEUTICS's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 28
2021
|
Jillian B. Thomsen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
75,000
-29.85%
|
$1,350,000
$18.62 P/Share
|
|
Jan 28
2021
|
Jillian B. Thomsen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
75,000
+13.96%
|
$600,000
$8.8 P/Share
|
|
Jan 05
2021
|
R Scott Greer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+15.06%
|
$520,000
$13.8 P/Share
|
|
Dec 30
2020
|
Roy A Whitfield Director |
BUY
Bona fide gift
|
Indirect |
51,500
+50.0%
|
-
|
|
Dec 30
2020
|
Roy A Whitfield Director |
SELL
Bona fide gift
|
Direct |
51,500
-21.7%
|
-
|
|
Dec 18
2020
|
Gil M Labrucherie SVP, COO & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+13.03%
|
-
|
|
Dec 18
2020
|
John Northcott SVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,550
+11.1%
|
-
|
|
Dec 18
2020
|
Howard W Robin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
106,650
+18.86%
|
-
|
|
Dec 18
2020
|
Jillian B. Thomsen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+8.32%
|
-
|
|
Dec 18
2020
|
Mark Andrew Wilson Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,550
+26.57%
|
-
|
|
Dec 18
2020
|
Jonathan Zalevsky Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+12.11%
|
-
|
|
Dec 15
2020
|
Myriam Curet Director |
SELL
Open market or private sale
|
Direct |
1,560
-7.5%
|
$26,520
$17.82 P/Share
|
|
Nov 23
2020
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
16,380
-6.14%
|
$262,080
$16.4 P/Share
|
|
Nov 16
2020
|
Gil M Labrucherie SVP, COO & CFO |
SELL
Open market or private sale
|
Direct |
8,276
-3.52%
|
$132,416
$16.93 P/Share
|
|
Nov 16
2020
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
11,975
-3.29%
|
$191,600
$16.93 P/Share
|
|
Nov 16
2020
|
Jillian B. Thomsen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,976
-6.97%
|
$191,616
$16.93 P/Share
|
|
Nov 16
2020
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,539
-2.99%
|
$24,624
$16.93 P/Share
|
|
Nov 16
2020
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
29,618
-10.0%
|
$473,888
$16.93 P/Share
|
|
Sep 28
2020
|
Jeffrey Robert Ajer Director |
SELL
Open market or private sale
|
Direct |
3,250
-11.12%
|
$55,250
$17.25 P/Share
|